Predictors of persistent disease following initial thyroid cancer management

References

1. ↵
   1. Mao Y,
   2. Xing M

   (2016) Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 23:313–322.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Al-Shahrani Z,
   2. Al-Rawaji A,
   3. Al-Madouj A,
   4. Alomran F,
   5. Alzahrani W,
   6. Almutalq H,
   7. et al.

   (2016) Cancer Incidence Report, Saudi Arabia 2016 (Saudi Health Council, Saudi Cancer Registry, Riyadh (KSA)) Available from URL:https://nhic.gov.sa/eServices/Documents/E%20SCR%20final%206%20NOV.pdf. Updated September 2018. February 2020.
3. ↵
   1. La Vecchia C,
   2. Malvezzi M,
   3. Bosetti C,
   4. Garavello W,
   5. Bertuccio P,
   6. Levi F,
   7. et al.

   (2015) Thyroid cancer mortality and incidence:a global overview. Int J Cancer 136:2187–2195.

   OpenUrl
4. ↵
   1. Sapuppo G,
   2. Tavarelli M,
   3. Belfiore A,
   4. Vigneri R,
   5. Pellegriti G

   (2019) Time to separate persistent from recurrent differentiated thyroid cancer:different conditions with different outcomes. J Clin Endocrinol Metab 104:258–265.

   OpenUrlCrossRefPubMed
5. ↵
   1. Algeciras-Schimnich A

   (2018) (2018) Thyroglobulin measurement in the management of patients with differentiated thyroid cancer. Crit Rev Clin Lab Sci 55:205–218.

   OpenUrl
6. ↵
   1. Haugen BR,
   2. Alexander EK,
   3. Bible KC,
   4. Doherty GM,
   5. Mandel SM,
   6. Nikiforov YE,
   7. et al.

   (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1–133.

   OpenUrlCrossRefPubMed
7. ↵
   1. Park S,
   2. Kim WG,
   3. Song E,
   4. Oh HS,
   5. Kim M,
   6. Kwon H,
   7. et al.

   (2017) Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. Thyroid 27:524–530.

   OpenUrl
8. ↵
   1. Leon MJ,
   2. Kim M,
   3. Park S,
   4. Oh HS,
   5. Kim TY,
   6. Kim WB,
   7. et al.

   (2018) A follow-up strategy for patients with an excellent response to initial therapy for differentiated thyroid carcinoma:Less is better. Thyroid 28:187–192.

   OpenUrl
9. 1. Tuttle RM,
   2. Alzahrani AS

   (2019) Risk stratification in differentiated thyroid cancer:From detection to final follow-up. J Clin Endocrinol Metab 104:4087–100.

   OpenUrl
10. ↵
    1. Amin MB,
    2. Edge S,
    3. Greene F,
    4. Byrd DR,
    5. Brookland RK,
    6. Washington MK,
    7. et al.

    (2017) AJCC Cancer Staging Manual (Springer International Publishing:American Joint Commission on Cancer, New York (NY)), 8th ed.
11. ↵
    1. Alzahrani AS,
    2. Alomar H,
    3. Alzahrani N

    (2017) Thyroid Cancer in Saudi Arabia:A Histopathological and Outcome Study. Int J Endocrinol 2017:8423147.

    OpenUrl
12. ↵
    1. de Castro TP,
    2. Waissmann W,
    3. Simões TC,
    4. de Mello RC,
    5. Carvalho DP

    (2016) Predictors for papillary thyroid cancer persistence and recurrence:a retrospective analysis with a 10-year follow-up cohort study. Clin Endocrinol (Oxf) 85:466–474.

    OpenUrl
13. ↵
    1. Barbosa MP,
    2. Momesso D,
    3. Bulzico DA,
    4. Farias T,
    5. Dias F,
    6. Lima RA,
    7. Corbo R,
    8. Vaisman M,
    9. Vaisman F

    (2017) Metastatic lymph node characteristics as predictors of recurrence/persistence in the neck and distant metastases in differentiated thyroid cancer. Arch Endocrinol Metab 61:584–589.

    OpenUrl
14. ↵
    1. Leboulleux S,
    2. Rubino C,
    3. Baudin E,
    4. Caillou B,
    5. Hartl DM,
    6. Bidart JM,
    7. et al.

    (2005) Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90:5723–5729.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Furtado Mde S,
    2. Rosario PW,
    3. Calsolari MR

    (2015) Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis. Arch Endocrinol Metab 59:285–291.

    OpenUrl
16. ↵
    1. Yeh MW,
    2. Bauer AJ,
    3. Bernet VA,
    4. Ferris RL,
    5. Loevner LA,
    6. Mandel SJ,
    7. et al.

    (2015) American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 25:3–14.

    OpenUrlCrossRefPubMed
17. ↵
    1. Khokhar M,
    2. Milas M

    (2019) Management of Nodal Disease in Thyroid Cancer. Surg Clin North Am 99:611–632.

    OpenUrl
18. ↵
    1. Sabra MM,
    2. Grewal RK,
    3. Ghossein RA,
    4. Tuttle RM

    (2014) Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid 24:1088–1095.

    OpenUrlCrossRefPubMed
19. ↵
    1. Kamel Hasan O,
    2. De Brabandere S,
    3. Rachinsky I,
    4. Laidley D,
    5. MacNeil D,
    6. Van Uum S

    (2020) Microscopic positive tumor margin increases risk for disease persistence but not recurrence in patients with stage T1-T2 differentiated thyroid cancer. J Thyroid Res 2020:52–7.

    OpenUrl
20. ↵
    1. Vuong HG,
    2. Kondo T,
    3. Duong UNP,
    4. Pham TQ,
    5. Oishi N,
    6. Mochizuki K,
    7. Nakazawa T,
    8. Hassell L,
    9. Katoh R

    (2017) Prognostic impact of vascular invasion in differentiated thyroid carcinoma:a systematic review and meta-analysis. Eur J Endocrinol 177:207–216.

    OpenUrlAbstract/FREE Full Text